CSI’s new Diamondback Peripheral 60cm systems receive FDA clearance for PAD treatment Cardiovascular Systems, Inc. Receiving FDA clearance for our fresh 60cm, 4 French devices demonstrates CSI's dedication to advancing technology and expanding the interventional market, said David L. Martin, CSI president and chief executive officer click to be linked . We're providing doctors with broader treatment plans for challenging lesions in the low leg, connected with Critical Limb Ischemia often, or CLI, which if still left untreated may bring about lower limb amputation.
CTI announces AIFA approval for produce of pixantrone at NerPharMa facility Cell Therapeutics, Inc. today announced that the Italian Medicines Agency , the national authority responsible for medication regulation in Italy, has approved the facility at NerPharMa DS for the creation of CTI’s drug candidate pixantrone. CTI is along the way of preparing a Marketing Authorization Application in europe for pixantrone to treat relapsed or refractory aggressive non-Hodgkin’s lymphoma . Philips, President of CTI. Â.